Scan to Download Gate App
qrCode
More Download Options
Don't remind me again today

Biopharma aims for $100 million for a cryptocurrency fund to support cancer treatment.

robot
Abstract generation in progress

Australian biotechnology company Propanc Biopharma has raised up to 100 million USD from Hexstone Capital, a family office specializing in cryptocurrency, to build a digital asset treasury and advance the PRP cancer therapy into human trials by 2026.

The agreement includes an initial investment of 1 million USD and a maximum of 99 million USD thereafter within 12 months. CEO James Nathanielsz stated that establishing a cryptocurrency treasury will help strengthen finances and support the company's “transformative” growth phase.

Propanc has not disclosed what type of digital asset it will purchase, but Hexstone has previously invested in Bitcoin, Ether, Solana, and Injective.

This move follows the trend of biotechnology companies like Sonnet BioTherapeutics shifting to cryptocurrency, yet Propanc's PPCB stock still fell 10.5% on Nasdaq and lost 46.7% over the past month.

BTC-0.95%
SOL-1.38%
INJ-1.52%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)